Related Experiment Video
Updated: Feb 12, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
The Immunogenicity and Anti-Tumor Efficacy of a Rationally Designed EGFR Vaccine
Chao Cheng1, Li Deng2, Rongxiu Li1
1State Key Laboratory of Microbial Metabolism and School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Background/Aims:
The abnormally activated EGFR promotes tumor growth, invasion and metastasis. Current therapeutics targeting EGFR have markedly improved the clinical outcome, but they are limited in use due to transient efficacy, frequent administration, high cost and significant toxicity.
Methods:
We rationally designed a multiepitope immunogen against EGFR, named as DEGFRm. The immunogen is composed of an epitope peptide (EGFR265-283) and the extracellular domain III (EGFR334-505) of mouse EGFR. EGFR265-283 is grafted onto the translocation domain of diphtheria toxin (DTT), and EGFR334-505 is fused to C-terminal of DTT. Next, the immunogenicity and anti-tumor efficacies of DEGFRm vaccine were examined in mouse tumor models.
Results:
When formulated with Alum and CpG, DEGFRm vaccine elicits Th 1 immune responses and inhibits tumor growth in both prophylactic and therapeutic mouse tumor models. Moreover, the tumor microvasculature is markedly reduced and the tumor infiltration of CD8+ T lymphocytes is greatly enhanced.
Conclusions:
These data suggest that active immunization with DEGFRm vaccine is a promising strategy for therapy of various EGFR+ cancers.
Insights
A novel multiepitope immunogen, DEGFRm, shows promise as a vaccine for EGFR+ cancers. This vaccine elicits immune responses and inhibits tumor growth in preclinical models, offering a potential new therapeutic strategy.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Abnormally activated Epidermal Growth Factor Receptor (EGFR) drives tumor progression, invasion, and metastasis.
- Current EGFR-targeted therapies offer clinical benefits but face limitations including transient efficacy, frequent dosing, high costs, and toxicity.
Purpose of the Study:
- To design and evaluate a novel multiepitope immunogen (DEGFRm) for active immunization against EGFR.
- To assess the immunogenicity and anti-tumor efficacy of the DEGFRm vaccine in preclinical cancer models.
Main Methods:
- A multiepitope immunogen, DEGFRm, was engineered by combining an epitope peptide (EGFR265-283) and the extracellular domain III (EGFR334-505) of mouse EGFR, fused to the diphtheria toxin translocation domain (DTT).
- The immunogenicity and anti-tumor effects of the DEGFRm vaccine were investigated in mouse tumor models, formulated with Alum and CpG adjuvants.
Main Results:
- The DEGFRm vaccine induced Th1 immune responses.
- Significant inhibition of tumor growth was observed in both prophylactic and therapeutic settings in mouse models.
- The vaccine treatment led to reduced tumor microvasculature and enhanced infiltration of CD8+ T lymphocytes into tumors.
Conclusions:
- Active immunization with the DEGFRm vaccine represents a promising therapeutic strategy for various EGFR-positive cancers.
- The vaccine's ability to elicit immune responses and inhibit tumor growth warrants further investigation for clinical application.
More Related Videos
Related Concept Videos
Vaccinations
Rationalizing Substitutions
Rational Expressions
Asymptotes in Rational Functions
Self-Efficacy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

